A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

Recruiting now · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC

In brief

This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.

Key facts

Study ID
NCT07365319
Run by
Eikon Therapeutics
People needed
750
Starts
2026-06-15
Expected to finish
2040-12-31
Last updated by the study team
2026-08-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.